Got a Question?
If you have a question for our guest, host or DRG please submit it here.
Addressing strategic challenges for biotech companies
Guest: Dr Srikanth Rajagopal, Consulting Partner, DRG
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at DRG Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. Doc gives invaluable insight for bio-pharma companies who are making development and/or commercializing decisions for their clinical programs both for those developing in house and those considering out licensing. He explores pertinent examples of how companies can go about understanding the commercial opportunity of their efficacious treatments in various scenarios and markets (including orphan indications) and discusses what he calls the 'magic triangle' to get an asset to market as fast as possible.
Highlights from this episode:
About our Guest
Dr Srikanth Rajagopal, Consulting Partner, DRG
Dr. Srikanth Rajagopal, is a Partner at DRG Consulting, based out of London. Doc has over 15 years global management experience. Areas of expertise include product and portfolio strategy, pricing, reimbursement and access across Europe and Emerging Markets, transaction advisory and commercial strategy. Doc’s recent vaccine experience includes digital / multi-marketing strategy for the UK business unit of a large multinational vaccines company, competitive risk assessment for the vaccines portfolio of a large multinational vaccines company and an assessment of compliance for vaccines across European markets. Doc holds an MBA from the Indian Institute of Management, Ahmedabad and an MBBS (MD equivalent) from the University of Mumbai.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.
Creating an accurate picture of your asset’s commercial options (7mins)
Guest: Dr Srikanth Rajagopal, Consulting Partner, DRG
In this Conversations in Healthcare highlight, Mike Ward, Global Head of Thought Leadership at DRG talks to DRG Consulting Partner, Dr Srikanth Rajagopal (or Doc, as he is fondly referred to) about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. In this highlight from the interview, Doc gives invaluable insight for biotechnology companies who are looking to assess the value of taking an asset forward into commercialisation. In our chat we explore pertinent examples of the decision science needed to accurately forecast and assign numbers to value, risk drivers and market level threats. We also touched on how companies can get an accurate picture of all their commercial options for example the trade-offs of proceeding in a crowded market or going back to the drawing board and finding ways to innovate and differentiate.
Understanding Commercial Opportunity for efficacious treatments (8mins)
Guest: Dr Srikanth Rajagopal, Consulting Partner, DRG
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at DRG Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. Doc provides invaluable insight for biopharma companies who are making development and/or commercial decisions for their clinical programs, both for those developing in house and those considering out-licensing. He explores pertinent examples of how companies can go about understanding the commercial opportunity of their efficacious treatments in various scenarios and markets (including orphan indications) and discusses what he calls the ‘magic triangle’ to get an asset to market as fast as possible.
Key commercial factors to consider during program development to forecast share of voice (11mins)
Guest: Dr Srikanth Rajagopal, Consulting Partner, DRG
In this Conversations in Healthcare highlight, Mike Ward, Global Head of Thought Leadership at DRG talks to DRG Consulting Partner, Dr Srikanth Rajagopal (or Doc, as he is fondly referred to) about the key approaches biotech management teams should be considering during asset development to ensure they can win share of patient and physician voice for their alternatives in crowded markets. Doc talks us through the importance of understanding the value and risks of differing in-house and out-license commercialisation alternatives and the interesting partnership discussions that are often triggered when companies think they have reached the end of the road with an asset.
